Annexin V release and transmembrane mitochondrial potential during storage of apheresis-derived platelets treated for pathogen reduction

Transfusion Medicine and Hemotherapy

Volumn 37, Issue 1, 2010, Pages 7-12

  Picker, Susanne M ^a   Oustianskaia, Larissa ^a   Schneider, Volker ^a   Gathof, Birgit S ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Endogenous annexin V; Intercept blood system; Mirasol PRT; Pathogen reduction technology; Platelet in vitro function; Transmembrane mitochondrial potential

Indexed keywords

LACTATE DEHYDROGENASE; LIPOCORTIN 5; PSORALEN; RIBOFLAVIN;

ARTICLE; BLOOD PH; CONTROLLED STUDY; ENZYME RELEASE; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; PROTEIN SECRETION; THROMBOCYTE COUNT; THROMBOCYTE PRESERVATION; THROMBOCYTOPHERESIS; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION;

EID: 77149130473     PISSN: 16603796     EISSN: None     Source Type: Journal    
DOI: 10.1159/000264666     Document Type: Article

References (29)

1. Knutson F, Alfonso R, Dupuis K, Mayaudon V, Lin L, Corash L, Högman CF: Photochemical inactivation of bacteria and HIV in buffy-coat derived platelet concentrates under conditions that preserve in vitro platelet function. Vox Sang 2000;78: 209-216.
2. Grass JA, Hei DJ, Metchette K, Cimino GD, Wiesehahn GP, Corash L, Lin L: Inactivation of leucocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood 1998; 91:2180-2188.
3. van Rhenen D, Gulliksson H, Cazenave JP, Pamphilon D, Ljungman P, Klüter H, Vermeij H, Kappers-Klunne M, de Greef G, Laforet M, Lioure B, Davis K, Marblie S, Mayaudon V, Flament J, Conlan M, Lin L, Metzel P, Buchholz D, Corash L: Transfusion of pooled buffy-coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003;101:2426-2433.
4. Goodrich L, Douglas I, Urioste M: Riboflavin photoinactivation procedure inactivates significant levels of bacteria and produces a culture negative product. Transfusion 2002;42:16S.
5. Goodrich L, Ghielli M, Hansen E, Woolum M, Gampp D, Goodrich R, Keil S: Riboflavin and UV light inactivate enveloped and non-enveloped viruses in platelet concentrates under conditions which maintain cell quality. Vox Sang 2002;83:111.
6. Ruane PH, Edrich R, Gampp D, Keil SD, Leonard RL, Goodrich RP: Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004; 44:877-885.
7. Verhoeven AJ, Verhaar R, Gouwerok EG, de Korte D: The mitochondrial membrane potential in human platelets: a sensitive parameter for platelet quality. Transfusion 2005;45:82-89.
8. Krailadsiri P, Seghatchian J, Amiral J, Vissac AM, Contreras M: Annexin V, a new marker of platelet storage lesion: correlation with dMPV. Transfus Sci 1997;18:223-226.
9. Swairjo MA, Concha NO, Kaetzel MA, Dedman JR, Seaton BA: Ca2+-bridging mechanism and phospholipid head group recognition in the membrane-binding protein Annexin V. Nat Struct Biol 1995;2:968-947.
10. Heerde van WL, Robert-Offerman S, Dumont E, Hofstra L, Doevendans PA, Smits JFM, Daemen MJAP, Reutelingsperger C: Markers of apoptosis in cardiovascular tissues: focus on annexin V. Cardiovasc Res 2000;45:549-559.
11. Bevers EM, Comfurius P, Zwaal RFA: Changes in membrane phospholipid distribution during platelet activation. Biochem Biophys Acta 1983;736:57-66.
12. Williamson P, Bevers EM, Smeets EF: Continuous analysis of the mechanism of activated transbilayer lipid movement in platelets. Biochemistry 1995;34:10448-10455.
13. Bratton DL, Fadok VA, Richter DA, Richter DA, Kailey JM, Guthrie LA, Henson PM: Appearance of phosphatidylserine on apoptotic cells requires calcium-mediated non-specific flip-flop and is enhanced by loss of aminophospholipid translocase. J Biol Chem 1997;272:26159-26165.
14. Verhoeven B, Schlegel RA, Williamson P: Mechanism of phosphatidylserine exposure, a phagocyte recognition signal on apoptotic T lymphocytes. J Exp Med 1995;182:1597-1601.
15. Reutelingsperger CP, van Heerde WL: Annexin V, the regulator of phosphatidyserine-catalyzed inflammation and coagulation during apoptosis. Cell Mol Life Sci 1997;53:527-532.
16. Romisch J, Schuler E, Bastian B, Bürger T, Dunkel FG, Schwinn A, Hartmann AA, Pâques EP: Annexin I to VI: quantitative determination in different human cell types and in plasma after myocardial infarction. Blood Coagul Fibrinol 1992;3:11-17.
17. Bundesärztekammer, Paul Ehrlich Institut: Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie). Überarbeitete Fassung, Köln, Deutscher Ärzteverlag, 2005.
18. Council of Europe: Guide to the preparation, use and quality assurance of blood components, 14th ed. Strassbourg, Council of Europe Publishing, 2008.
19. Lin R, Alfonso R, Behrman B, Corten L, Damonte PB, Dikeman R, Dupuis K, Hei D, Lin CY, Londe HF, Metchette K, Phan T, Reames AA, Rheinschmidt M, Savoor A, Tessman J, Corash L: Photochemical treatment of platelet concentrates with a novel psoralen and UVA to enhance the safety of platelet transfusions. Infusionsther Transfusionsmed 1998;25:39-48.
20. Janetzko K, Klinger M, Mayaudon V., Lin L, Eichler H, Klüter H: Storage characteristics of split double-dose platelet concentrates derived from apheresis and treated with amotosalen-HCl and UVA light for pathogen inactivation. Infus Ther Transfus Med 2002;29:193-198.
21. Picker SM, Speer R, Gathof BS: Functional characteristics of buffy-coat PLTs photochemically treated with amotosalen-HCl for pathogen inactivation. Transfusion 2004;44:320-329.
22. Li J, Lockerbie O, De Korte D, Rice J, McLean R, Goodrich RP: Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology. Transfusion 2005;45:920-926.
23. Perez-Pujol S, Tonda R, Lozano M, Fuste B, Lopez-Vilchez I, Galan AM, Li J, Goodrich R, Escolar G: Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion 2005;45:911-919.
24. Goodrich RP, Li J, Pieters H, Crookes R, Roodt J, Heyns AP: Correlation of in vitro platelet quality measurements with in vivo platelet viability in human subjects. Vox Sang 2006;90:279-285.
25. Picker SM, Steisel A, Gathof BS: Effects of MIRASOL PRT treatment on storage lesion development in plasma stored apheresis-derived platelets compared to untreated and irradiated units. Transfusion 2008;48:1685-1692.
26. Picker SM, Oustianskaia L, Schneider V, Gathof BS: Functional characteristics of apheresis-derived platelets treated with UV light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen reduction. Vox Sang 2009;97:26-33.
27. Li J, Xia Y, Bertino AM, Coburn JP, Kuter DJ: The mechanism of apoptosis in human platelets during storage. Transfusion 2000;40:1320-1329.
28. Picker SM, Steisel A, Gathof BS: Cell integrity mitochondrial function after MIRASOL-PRT treatment for pathogen reduction of apheresis-derived platelets: results of a 3-arm in-vitro study. Transfus Apher Sci 2009;40:79-85.
29. Gorlin JB (ed): Standards for Blood Banks and Transfusion Services, 21th ed. Bethesda, American Association of Blood Banks, 2002.